Literature DB >> 11595975

Viral hemorrhagic fever hazards for travelers in Africa.

M Isaäcson1.   

Abstract

This short review covers 6 viral hemorrhagic fevers (VHFs) that are known to occur in Africa: yellow fever, Rift Valley fever, Crimean-Congo hemorrhagic fever, Lassa fever, Marburg virus disease, and Ebola hemorrhagic fever. All of these have at one time or another affected travelers, often the adventurous kind who are "roughing it" in rural areas, who should therefore be made aware by their physicians or travel health clinics about their potential risk of exposure to any VHF along their travel route and how to minimize the risk. A significant proportion of VHF cases involving travelers have affected expatriate health care workers who were nosocomially exposed in African hospitals or clinics. The VHFs are associated with a high case-fatality rate but are readily prevented by well-known basic precautions.

Entities:  

Mesh:

Year:  2001        PMID: 11595975     DOI: 10.1086/322620

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

Review 1.  [Fever after travel return].

Authors:  I Schedel
Journal:  Internist (Berl)       Date:  2004-06       Impact factor: 0.743

2.  Cells expressing the RING finger Z protein are resistant to arenavirus infection.

Authors:  Tatjana I Cornu; Heinz Feldmann; Juan Carlos de la Torre
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Myristoylation of the RING finger Z protein is essential for arenavirus budding.

Authors:  Mar Perez; Dori L Greenwald; Juan Carlos de la Torre
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan.

Authors:  Stefan Kunz; Jillian M Rojek; Mar Perez; Christina F Spiropoulou; Michael B A Oldstone
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells.

Authors:  Benson Y H Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Vis Exp       Date:  2013-08-01       Impact factor: 1.355

6.  Arenavirus reverse genetics for vaccine development.

Authors:  Emilio Ortiz-Riaño; Benson Yee Hin Cheng; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Gen Virol       Date:  2013-01-30       Impact factor: 3.891

7.  Development of live-attenuated arenavirus vaccines based on codon deoptimization.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

8.  RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Ana B Sánchez; Mar Perez; Tatjana Cornu; Juan Carlos de la Torre
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Spectrum of Rift Valley fever virus transmission in Kenya: insights from three distinct regions.

Authors:  A Desiree LaBeaud; Yoshitsugu Ochiai; C J Peters; Eric M Muchiri; Charles H King
Journal:  Am J Trop Med Hyg       Date:  2007-05       Impact factor: 2.345

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.